Home › Companies › INTRA-CELLULAR THERAPIES INC. › 2024-2025

INTRA-CELLULAR THERAPIES INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed March 27, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

  • 11Reported items
  • 403Asset managers
  • 1,392Fund votes
  • March 27, 2025Meeting date

Results at a glance

Meeting of March 27, 2025: 2 items on INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed March 27, 2025: 2 without a stated outcome.

Material dissent

  • 2. The Merger-Related Compensation Proposal 62% of votes cast Outcome not stated Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore INTRA-CELLULAR THERAPIES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by INTRA-CELLULAR THERAPIES INC.

These tallies are INTRA-CELLULAR THERAPIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INTRA-CELLULAR THERAPIES INC. — official shareholder meeting results, meeting held March 27, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. The Merger Agreement Proposal 77,685,02488,362176,174 --0 99.8%Not verified—
2. The Merger-Related Compensation Proposal 48,312,17829,129,164508,215 --0 62%Not verified—

Source: INTRA-CELLULAR THERAPIES INC., Form 8-K, filed with the SEC on March 27, 2025 — read the filing on EDGAR.

How asset managers voted at the INTRA-CELLULAR THERAPIES INC. 2024-2025 meeting

Each item below shows how the 403 asset managers that disclosed a INTRA-CELLULAR THERAPIES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INTRA-CELLULAR THERAPIES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated…

No official matchEXTRAORDINARY TRANSACTIONS

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 95 asset managers

Description as filed by funds: To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated January 10, 2025, by and among Intra-Cellular Therapies, Inc. ("ITI"), Johnson & Johnson, a New Jersey corporation ("Johnson & Johnson"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into ITI (the "Merger"), with ITI surviving the Merger as a wholly owned subsidiary of Johnson & Johnson.

The 95 asset managers below reported 24,201,346 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 24,201,346
Largest asset managers voting on “To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), da” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,384,2580 00For
Fidelity3,698,7840 00For
BlackRock2,560,5160 00For
Invesco1,562,7150 00For
Charles Schwab895,6000 00For
First Trust683,1620 00For
JPMorgan505,7690 00For
TIAA467,9420 00For
MERGER FUND412,9650 00For
Jackson National316,5500 00For
FRANKLIN STRATEGIC SERIES296,4480 00For
Investment Managers Series Trust II235,8840 00For
Putnam220,8900 00For
AB DISCOVERY GROWTH FUND, INC.215,9730 00For
John Hancock187,7990 00For
AllianceBernstein176,4490 00For
NEXPOINT FUNDS I160,7000 00For
AMG FUNDS148,7740 00For
Manager Directed Portfolios140,3530 00For
Calamos119,6180 00For
Equitable109,3530 00For
State Street108,1400 00For
GMO97,5530 00For
MassMutual94,5450 00For
Principal86,6790 00For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

2. Approve Merger Agreement

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 6 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 4 asset managers voting on “Approve Merger Agreement” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Brighthouse109,6760 00For
GuideStone13,6960 00For
HC CAPITAL TRUST2,1060 00For
Simplify Exchange Traded Funds380 00For

Fund voting reports, all 4 managers: 125,516 for.

Institutional-manager reports: 2 asset managers voting on “Approve Merger Agreement” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH23,4000 00For
VOISARD ASSET MANAGEMENT GROUP, INC.70 00For

Institutional-manager reports, all 2 managers: 23,407 for.

3. Approve Merger Agreement To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger…

No official matchEXTRAORDINARY TRANSACTIONS

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 2 asset managers

Description as filed by funds: Approve Merger Agreement To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated January 10, 2025, by and among Intra-Cellular Therapies, Inc. ("ITI"), Johnson & Johnson, a New Jersey corporation ("Johnson & Johnson"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into ITI (the "Merger"), with ITI surviving the Merger as a wholly owned subsidiary of Johnson & Johnson.

The 2 asset managers below reported 13,290 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 13,290
Largest asset managers voting on “Approve Merger Agreement To adopt the Agreement and Plan of Merger (as it may be amended from time to time, th” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RBB FUND, INC.8,3750 00For
Dunham Funds4,9150 00For

4. TO ADJOURN THE COMPANY STOCKHOLDERS' MEETING TO A LATER DATE OR DATES AS PROVIDED IN THE MERGER AGREEMENT, IF NECESSARY…

No official matchCORPORATE GOVERNANCE

Combines 4 wordings of this item as funds reported it.

93% of fund votes cast · no official result

FOR
Details: description as filed, votes by 95 asset managers

Description as filed by funds: TO ADJOURN THE COMPANY STOCKHOLDERS' MEETING TO A LATER DATE OR DATES AS PROVIDED IN THE MERGER AGREEMENT, IF NECESSARY OR APPROPRIATE, INCLUDING TO SOLICIT ADDITIONAL VOTES IF THERE ARE INSUFFICIENT VOTES TO ADOPT THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING OF STOCKHOLDERS.

The 95 asset managers below reported 22,481,350 for, 1,713,720 against, 4,509 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 22,481,350AGAINST: 1,713,720ABSTAIN: 4,509
Largest asset managers voting on “TO ADJOURN THE COMPANY STOCKHOLDERS' MEETING TO A LATER DATE OR DATES AS PROVIDED IN THE MERGER AGREEMENT, IF ” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,384,2580 00For
Fidelity2,134,4761,564,308 00Mixed
BlackRock2,560,5160 00For
Invesco1,562,7150 00For
Charles Schwab895,6000 00For
First Trust683,1620 00For
JPMorgan505,7690 00For
TIAA467,9420 00For
MERGER FUND412,9650 00For
Jackson National316,5500 00For
FRANKLIN STRATEGIC SERIES296,4480 00For
Investment Managers Series Trust II235,8840 00For
Putnam220,8900 00For
AB DISCOVERY GROWTH FUND, INC.215,9730 00For
John Hancock187,7990 00For
AllianceBernstein176,4490 00For
NEXPOINT FUNDS I160,7000 00For
AMG FUNDS148,7740 00For
Manager Directed Portfolios140,3530 00For
Calamos119,6180 00For
Equitable109,3530 00For
State Street0108,140 00Against
GMO97,5530 00For
MassMutual94,5450 00For
Principal86,6790 00For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

5. Adjourn Meeting

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 4 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 3 asset managers voting on “Adjourn Meeting” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Brighthouse109,6760 00For
GuideStone13,6960 00For
HC CAPITAL TRUST2,1060 00For

Fund voting reports, all 3 managers: 125,478 for.

Institutional-manager reports: 1 asset manager voting on “Adjourn Meeting” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH23,4000 00For

Institutional-manager reports, all 1 managers: 23,400 for.

6. Approve Motion to Adjourn Meeting

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 2 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 1 asset manager voting on “Approve Motion to Adjourn Meeting” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds380 00For

Fund voting reports, all 1 managers: 38 for.

Institutional-manager reports: 1 asset manager voting on “Approve Motion to Adjourn Meeting” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
VOISARD ASSET MANAGEMENT GROUP, INC.70 00For

Institutional-manager reports, all 1 managers: 7 for.

7. Approve Motion to Adjourn Meeting To adjourn the Company Stockholders' Meeting to a later date or dates as provided in…

No official matchCORPORATE GOVERNANCE

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 2 asset managers

Description as filed by funds: Approve Motion to Adjourn Meeting To adjourn the Company Stockholders' Meeting to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, including to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting of Stockholders.

The 2 asset managers below reported 13,290 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 13,290
Largest asset managers voting on “Approve Motion to Adjourn Meeting To adjourn the Company Stockholders' Meeting to a later date or dates as pro” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RBB FUND, INC.8,3750 00For
Dunham Funds4,9150 00For

8. To approve, on an advisory (non- binding) basis, the compensation that may be paid or become payable to ITI's named…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 8 wordings of this item as funds reported it.

63% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 389 asset managers

Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation that may be paid or become payable to ITI's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 95 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation that may be paid or become payable to ITI's ” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,384,2580 00For
Fidelity161,2273,537,557 00Against
BlackRock2,560,5160 00For
Invesco1,562,7150 00For
Charles Schwab895,6000 00For
First Trust7,356675,806 00Against
JPMorgan0505,769 00Against
TIAA0467,942 00Against
MERGER FUND412,9650 00For
Jackson National257,05259,498 00Mixed
FRANKLIN STRATEGIC SERIES296,4480 00For
Investment Managers Series Trust II235,8840 00For
Putnam0220,890 00Against
AB DISCOVERY GROWTH FUND, INC.0215,973 00Against
John Hancock80,825106,974 00Mixed
AllianceBernstein0176,449 00Against
NEXPOINT FUNDS I160,7000 00For
AMG FUNDS148,7740 00For
Manager Directed Portfolios140,3530 00For
Calamos119,6180 00For
Equitable7,589101,764 00Mixed
State Street108,1400 00For
GMO097,553 00Against
MassMutual94,5450 00For
Principal58,08028,599 00Mixed

Fund voting reports, all 95 managers: 17,256,024 for, 6,939,046 against, 1 withheld, 4,509 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 318 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation that may be paid or become payable to ITI's ” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Pentwater Capital Management LP04,304,480 00Against
BlackRock3,170,13627,156 00For
FARALLON CAPITAL MANAGEMENT LLC3,054,5470 00For
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP2,998,9660 00For
Fidelity02,655,300 00Against
Deep Track Capital, LP2,000,0000 00For
Invesco1,846,2410 00For
GEODE CAPITAL MANAGEMENT, LLC01,751,292 00Against
State Street1,518,56646,946 00For
MARSHALL WACE, LLP1,410,3310 00For
AllianceBernstein0969,613 00Against
Charles Schwab905,2320 00For
GW&K Investment Management, LLC113,2240 00For
UBS0821,757 00Against
Hudson Bay Capital Management LP0806,475 00Against
PERCEPTIVE ADVISORS LLC760,6740 00For
Avoro Capital Advisors LLC742,5000 00For
SUVRETTA CAPITAL MANAGEMENT, LLC700,9040 00For
TIG Advisors, LLC591,6290 00For
Citadel539,3970 00For
Northern Trust0509,557 00Against
DE Shaw0490,385 00Against
TUDOR INVESTMENT CORP ET AL487,0000 00For
Nuveen0476,432 00Against
GLAZER CAPITAL, LLC0467,849 00Against

Institutional-manager reports, all 318 managers: 27,141,263 for, 19,624,164 against, 11,516 withheld, 406,199 abstained, 4,633 not voted, 758,294 mixed. Showing the 25 largest; see all in the interactive database.

9. Advisory Vote on Golden Parachutes

Combines 2 wordings of this item as funds reported it.

37% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: votes by 12 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 4 asset managers voting on “Advisory Vote on Golden Parachutes” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Brighthouse109,6760 00For
GuideStone013,696 00Against
AMERICAN BEACON FUNDS3,8000 00For
HC CAPITAL TRUST02,106 00Against

Fund voting reports, all 4 managers: 113,476 for, 15,802 against.

Institutional-manager reports: 8 asset managers voting on “Advisory Vote on Golden Parachutes” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Bellevue Group AG0925,701 00Against
JPMorgan0842,270 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.775,0000 00For
Taconic Capital Advisors LP225,0210 00For
ESSEX INVESTMENT MANAGEMENT CO LLC044,198 00Against
EFG Asset Management (North America) Corp.032,136 00Against
Erste Asset Management GmbH023,400 00Against
FAYEZ SAROFIM & CO430 00For

Institutional-manager reports, all 8 managers: 1,000,064 for, 1,867,705 against.

10. 14A Executive Compensation

No official matchSECTION 14A SAY-ON-PAY VOTES

100% of fund votes cast · no official result

ABSTAIN
Details: votes by 3 asset managers

The 3 asset managers below reported 45 for, 11,111 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 45ABSTAIN: 11,111
Largest asset managers voting on “14A Executive Compensation” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
DeepCurrents Investment Group LLC00 11,1110Abstain
Simplify Exchange Traded Funds380 00For
VOISARD ASSET MANAGEMENT GROUP, INC.70 00For

11. 14A Executive Compensation To approve, on an advisory (non-binding) basis, the compensation that may be paid or become…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 3 asset managers

Description as filed by funds: 14A Executive Compensation To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to ITI's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 2 asset managers voting on “14A Executive Compensation To approve, on an advisory (non-binding) basis, the compensation that may be paid o” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RBB FUND, INC.8,3750 00For
Dunham Funds4,9150 00For

Fund voting reports, all 2 managers: 13,290 for.

Institutional-manager reports: 1 asset manager voting on “14A Executive Compensation To approve, on an advisory (non-binding) basis, the compensation that may be paid o” at INTRA-CELLULAR THERAPIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Pier Capital, LLC36,2870 00For

Institutional-manager reports, all 1 managers: 36,287 for.

Not shown here: this season’s fund filings also report 1 item from the meeting of June 14, 2024, which belongs to the 2023-2024 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest INTRA-CELLULAR THERAPIES INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.

Fund voting reports: top INTRA-CELLULAR THERAPIES INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation that may be paid or become…”, 2024-2025
#Asset manager Shares voted
1Vanguard 9,384,258
2Fidelity 3,698,784
3BlackRock 2,560,516
4Invesco 1,562,715
5Charles Schwab 895,600
6First Trust 683,162
7JPMorgan 505,769
8TIAA 467,942
9MERGER FUND 412,965
10Jackson National 316,550
Institutional-manager reports: top INTRA-CELLULAR THERAPIES INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation that may be paid or become…”, 2024-2025
#Asset manager Shares voted
1Pentwater Capital Management LP 4,304,480
2BlackRock 3,197,292
3FARALLON CAPITAL MANAGEMENT LLC 3,054,547
4DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 2,998,966
5Fidelity 2,655,300
6Deep Track Capital, LP 2,000,000
7Invesco 1,846,241
8GEODE CAPITAL MANAGEMENT, LLC 1,751,292
9State Street 1,565,512
10MARSHALL WACE, LLP 1,410,331

Shown as share counts, not percentages: no shares-outstanding figure has been matched to INTRA-CELLULAR THERAPIES INC. for the 2024-2025 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At INTRA-CELLULAR THERAPIES INC.'s shareholder meeting held March 27, 2025, in the 2024-2025 proxy season, 403 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,392 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. INTRA-CELLULAR THERAPIES INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory (non- binding) basis, the compensation that may be paid or become… — the reporting funds and managers cast 63% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

INTRA-CELLULAR THERAPIES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Download data (CSV): ballot items · votes by manager · column guide.